Skyepharma Share Discussion Threads

[polaris] 08/2/2016 16:14

well this is an interesting one. Can't see any logical reason for a 40p fall, yet there it is. With SKP in a closed period up to the results then not as if they can say anything. I think this happened before in the recent past and it was all on hearsay that had no credence and the share price went back up to pre-close levels at the results.

Just one for the traders - i.e. me - to look at and weigh.

regards,

Paul

[aceuk] 08/2/2016 16:05

It's risk-off mode, that's all

[cap160] 08/2/2016 15:41

Hope there's not a rights issue or something lurking in the background

[pooroldboy55] 08/2/2016 14:27

I agree but 30p down thats going some

[kfp] 08/2/2016 12:56

You have to understand a stock with small number of shares in existence that have thin trades, that's why when there is any good news you cant get in and any negative news and you can only get out in small numbers ?
That's the risk.
Could be the odd bod who always sell's when results are around in case of any negatives, I hope !

[pooroldboy55] 08/2/2016 12:36

I think something going on or someone knows what ?? down 6% and still falling

[soundbuy] 08/2/2016 11:41

Not a lot, off(ish) day, low vols, liquidity, bid can drop 5p with 2k shed (or less).........

[diesel] 08/2/2016 11:38

Maybe an isn't. is off loading more stock, the announcement of results can't be more than coincidence, they are much the same time each year.

[pooroldboy55] 08/2/2016 11:31

Now down 20p ,whats going on??????

[fhmktg] 08/2/2016 09:32

Downwards squeeze on the sp, ahead of the results?

[diesel] 01/2/2016 18:05

Back to SKP matters...a huge amount of buying at 350 today, didn't move the price, so I'm guessing there is a seller offloading or a overhang, either way shows a good appetite for stock.

[kfp] 31/1/2016 16:45

What a shame ,after so many years of sensible post we have a moron.
Price of success I suppose !

[m2m] 31/1/2016 15:42

Dear market sniper3,

Has someone hacked your account or you may wish to add yourself to that list?

Regards

m2m

[diesel] 28/1/2016 16:26

How disappointing....

[mrx9000] 28/1/2016 15:56

My advice in regard the above and the below user is just to filter him. I have done a new thread on advfn that lists Keyboard Warriors and Trolls here


Feel free to utilise.

[mrx9000] 28/1/2016 14:13

My advice in regard the above user is just to filter him. I have done a new thread on advfn that lists Keyboard Warriors and Trolls here

[market sniper3] 28/1/2016 14:07

N+1 Singer Reiterates “CorporateR21; Rating for SkyePharma PLC (SKP)
January 28th, 2016 • 0 comments • Filed Under • by ABMN Staff

SkyePharma PLC logoSkyePharma PLC (LON:SKP)‘s stock had its “corporateR21; rating reiterated by N+1 Singer in a research report issued to clients and investors on Thursday, Market Beat Ratings reports.

Shares of SkyePharma PLC (LON:SKP) opened at 393.2500 on Thursday. The firm’s market cap is GBX 412.13 million. SkyePharma PLC has a 52 week low of GBX 247.00 and a 52 week high of GBX 414.45. The firm’s 50-day moving average price is GBX 373.99 and its 200-day moving average price is GBX 328.49.



Other research analysts also recently issued research reports about the company. Stifel Nicolaus reiterated a “buy” rating and set a GBX 460 ($6.55) price target on shares of SkyePharma PLC in a report on Thursday. FinnCap reiterated a “buy” rating on shares of SkyePharma PLC in a report on Friday, January 22nd. Finally, RX Securities reiterated a “buy” rating on shares of SkyePharma PLC in a report on Wednesday, December 23rd.

Skyepharma PLC (LON:SKP) is a specialty pharmaceutical company. The Company is engaged in the development and delivery of oral and inhalation pharmaceutical products. The Company’s products pipeline includes four inhalation products, 10 oral products, one topical product and one injectable product. The Company’s products include flutiform, Exparel, Paxil CR, Sular, Diclofenacratiopharm, Madopar DR and Coruno, among others. The Company’s product flutiform is a multi-dose pressurized metered dose inhaler, utilizing SkyeDry technology, containing steroid (fluticasone) and a beta agonist (formoterol). flutiform is indicated for the treatment of asthma. Exparel is a bupivacaine injectable product indicated for post-surgical pain management. The Product utilizes Pacira Pharmaceuticals̵7; DepoFoam technology. The Company has approximately 10 approved oral products that are sold in over 80 countries.

[market sniper3] 28/1/2016 12:43

SkyePharma PLC’s (SKP) “Buy” Rating Reiterated at Stifel Nicolaus
January 28th, 2016 • 0 comments • Filed Under • by ABMN Staff

SkyePharma PLC logoSkyePharma PLC (LON:SKP)‘s stock had its “buy” rating reaffirmed by investment analysts at Stifel Nicolaus in a note issued to investors on Thursday, MarketBeat reports. They presently have a GBX 460 ($6.55) price objective on the stock. Stifel Nicolaus’ price target would suggest a potential upside of 17.50% from the stock’s current price.

A number of other research firms have also recently commented on SKP. N+1 Singer restated a “corporateR21; rating on shares of SkyePharma PLC in a report on Wednesday, December 16th. RX Securities restated a “buy” rating on shares of SkyePharma PLC in a report on Wednesday, December 23rd. Finally, FinnCap restated a “buy” rating on shares of SkyePharma PLC in a report on Friday, January 22nd.



Shares of SkyePharma PLC (LON:SKP) opened at 393.2500 on Thursday. The stock has a 50 day moving average of GBX 373.99 and a 200-day moving average of GBX 328.49. SkyePharma PLC has a 52 week low of GBX 247.00 and a 52 week high of GBX 414.45. The company’s market capitalization is GBX 412.13 million.

Skyepharma PLC (LON:SKP) is a specialty pharmaceutical company. The Company is engaged in the development and delivery of oral and inhalation pharmaceutical products. The Company’s products pipeline includes four inhalation products, 10 oral products, one topical product and one injectable product. The Company’s products include flutiform, Exparel, Paxil CR, Sular, Diclofenacratiopharm, Madopar DR and Coruno, among others. The Company’s product flutiform is a multi-dose pressurized metered dose inhaler, utilizing SkyeDry technology, containing steroid (fluticasone) and a beta agonist (formoterol). flutiform is indicated for the treatment of asthma. Exparel is a bupivacaine injectable product indicated for post-surgical pain management. The Product utilizes Pacira Pharmaceuticals̵7; DepoFoam technology. The Company has approximately 10 approved oral products that are sold in over 80 countries.